Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Sponsor
Ipsen
Study ID
NCT07314164
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs). These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow. The study will take place in regular hospitals and clinics in Germany and Austria. It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life. This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.

Key Dates

Start date
Dec 17, 2025
Status verified
May 2026
Primary completion
Oct 31, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
150 participants (estimated)

Primary Outcome Measure

Disease Control Rate (DCR) [ Time Frame: At 6 Months ]

Central Contacts

Related Studies